This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Extended Release Drugs Market

Market Insights on Extended Release Drugs covering sales outlook, demand forecast & up-to-date key trends

Extended Release Drugs Market By Drug Release, Distribution Channel & Region - Forecast 2022 – 2032

Extended Release Drugs Market Outlook (2022-2032)

[250 Pages Report] Sales in the extended release drugs market are expected to rise at a CAGR of 11% over the forecast period 2022-2032. Extended release drugs market is currently valued at US$ 48 Bn. Due to changes in the prescription patterns and rising acceptance of diverse dosage forms, demand for extended release drugs is anticipated to bolster in the forthcoming years.

Report Attribute

Details

Extended Release Drugs Market Size (2022)

US$ 48 Bn

Extended Release Drugs Market Projected Growth Rate (2022-2032)

11% CAGR

Conventional drugs release the active ingredient as soon as they are administered. Drug delivery systems are planned technologies that deliver the active ingredient in a controlled environment, controlling the time, rate, and area of drug release in the body. These systems have been proven to be safe and efficient.

Extended release drugs is a dosage formulation that reduces the dosage by half. There are specific regulations released by the FDA that extended release drugs need to comply with.

Growing adoption of various drug delivery systems by doctors and patients, safety and effectiveness of extended drug release, and a reduction in medical care expenditure due to extended release drugs will create a conducive environment for the growth in the market.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Trends Influencing Sales of Extended Release Drugs?  

Compared to conventional oral drugs, extended release drugs are well-planned administration of medication. Extended release drugs control the time, area, and rate of the dosage, thereby increasing the safety and efficacy. With controlled release of the active ingredient, extended release drugs also help to reduce the frequency of dosage, resulting in easier and better acceptance by patients as well as increased bioavailability.

Further, growing demand for pediatric and geriatric extended drug release formulations, widespread acceptance of extended drug release systems, and notable changes in the prescription pattern of doctors will drive the market.

Advancing research & development, ongoing clinical trials in the pharmaceutical sector, and greater focus on the development of new and innovative therapeutics will further bolster the market for extended drug release.

What are the Limitations for Extended Release Drug Manufacturers?

The cost of extended drug release is a major roadblock for manufacturers. A single unit of extended release drugs costs double or triple the conventional oral dosage. The price of Namenda extended release drug is around US$ 494 for 7mg. This is expected to limit sales in the market.

Conventional drugs have an almost immediate impact whereas extended release drugs take a comparatively long time to make an impact as they have a slower course of action.

Side effects such as dose dumping could seriously affect health, which might hamper the growth in the market.

Dose dumping is the quick release of extended release drugs in the circulatory system and can lead to toxicity. Refusal of extended release drugs due to bad taste or swallowing difficulties is another factor that may impede demand in the forthcoming years.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the North America Extended Release Drug Market Outlook?

Owing to the introduction of new and innovative therapeutics and their widespread acceptance, North America holds a significant share in the global extended release drugs market. Presence of leading pharmaceutical and biopharmaceutical companies, along with increasing investments in research and development in the pharmaceutical sector will propel the growth in the North America extended release drug market.

The growing burden of chronic diseases and adoption of extended release drugs in treatment of hypertension will further underpin the demand for extended release drugs.

What are the Sales Prospects for Extended Release Drugs in Europe?

Increasing adoption of extended release drugs across countries such as Germany, the U.K., Italy and France is expected to boost the Europe extended release market over the assessment period.

Rising incidence of chronic diseases such as COPD, diabetes, and cancer has led to quicker adoption of extended release drugs. This is expected to create opportunities for extended release drug manufacturers operating in Europe.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

What is the Scope for Extended Release Drugs Market in Asia Pacific?

As per FMI, Asia Pacific is predicted to display the highest CAGR during the forecast period. The region has shown great potential in extended release drugs market due to rapid growth of the pharmaceutical industry.

Ongoing expansion of the pharmaceutical and biopharmaceutical sectors across countries including China and India is anticipated to steer sales in the Asia Pacific extended release drugs market.

Market Competition

Some of the key players in the the global extended release drugs market are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, and Ranbaxy.

The global extended release drug market is a highly competitive with leading companies focusing on developing novel therapeutics. Mergers and acquisitions are the go-to strategies adopted by key players to expand their product portfolios.

Report Scope

Report Attribute

Details

Growth Rate

CAGR 11% of   from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Million, and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Release
  • Distribution Channel
  • Region

Countries Covered

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

Key Companies Profiled

  • Pfizer
  • Mallinckrodt
  • Actavis
  • Janssen Pharmaceuticals
  • Endo Pharmaceuticals
  • Purdue Pharma
  • Lavipharm Labs
  • Mylan Technologies
  • Noven
  • Aveva
  • Watson
  •  Impax
  • Ranbaxy 

Customization

Available Upon Request

Key Segments Profiled in the Extended Release Drug Market Survey

By Drug Release:

  • Sustained release
  • Controlled Release

By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Mail order pharmacies
  • Drug Stores

By Region:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

Frequently Asked Questions

Due to the rapid growth of the pharmaceutical industry, especially in India and China, Asia Pacific is expected to emerge as an attractive market for extended release drugs.

Leading players present in the global extended release drug market include Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, and Ranbaxy.

Rising demand for pediatric and geriatric extended drug release formulations, and ongoing clinical trials in the pharmaceutical sector are some trends that are expected to drive sales of extended release drugs.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Release

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Drug Release, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Drug Release, 2022-2032

        5.3.1. Sustained Release

        5.3.2. Controlled Release

    5.4. Y-o-Y Growth Trend Analysis By Drug Release, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Release, 2022-2032

6. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distributional Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Distributional Channel, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2022-2032

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Mail Order Pharmacies

        6.3.4. Drug Stores

    6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2022-2032

7. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Region, 2017-2021

    7.3. Current Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. East Asia

        7.3.5. South Asia & Pacific

        7.3.6. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Release

        8.2.3. By Distributional Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Release

        8.3.3. By Distributional Channel

    8.4. Key Takeaways

9. Latin America Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Release

        9.2.3. By Distributional Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Release

        9.3.3. By Distributional Channel

    9.4. Key Takeaways

10. Europe Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Release

        10.2.3. By Distributional Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Release

        10.3.3. By Distributional Channel

    10.4. Key Takeaways

11. East Asia Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

        11.2.2. By Drug Release

        11.2.3. By Distributional Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Release

        11.3.3. By Distributional Channel

    11.4. Key Takeaways

12. South Asia & Pacific Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Thailand

            12.2.1.3. Indonesia

            12.2.1.4. Malaysia

            12.2.1.5. Singapore

            12.2.1.6. Australia

            12.2.1.7. New Zealand

            12.2.1.8. Rest of South Asia & Pacific

        12.2.2. By Drug Release

        12.2.3. By Distributional Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Release

        12.3.3. By Distributional Channel

    12.4. Key Takeaways

13. MEA Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug Release

        13.2.3. By Distributional Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Release

        13.3.3. By Distributional Channel

    13.4. Key Takeaways

14. Key Countries Extended Release Drugs Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Drug Release

            14.1.2.2. By Distributional Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Drug Release

            14.2.2.2. By Distributional Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Drug Release

            14.3.2.2. By Distributional Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Drug Release

            14.4.2.2. By Distributional Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Drug Release

            14.5.2.2. By Distributional Channel

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Drug Release

            14.6.2.2. By Distributional Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Drug Release

            14.7.2.2. By Distributional Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Drug Release

            14.8.2.2. By Distributional Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Drug Release

            14.9.2.2. By Distributional Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Drug Release

            14.10.2.2. By Distributional Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Drug Release

            14.11.2.2. By Distributional Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Drug Release

            14.12.2.2. By Distributional Channel

    14.13. India

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Drug Release

            14.13.2.2. By Distributional Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Drug Release

            14.14.2.2. By Distributional Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Drug Release

            14.15.2.2. By Distributional Channel

    14.16. Malaysia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2021

            14.16.2.1. By Drug Release

            14.16.2.2. By Distributional Channel

    14.17. Singapore

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2021

            14.17.2.1. By Drug Release

            14.17.2.2. By Distributional Channel

    14.18. Australia

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2021

            14.18.2.1. By Drug Release

            14.18.2.2. By Distributional Channel

    14.19. New Zealand

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2021

            14.19.2.1. By Drug Release

            14.19.2.2. By Distributional Channel

    14.20. GCC Countries

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2021

            14.20.2.1. By Drug Release

            14.20.2.2. By Distributional Channel

    14.21. South Africa

        14.21.1. Pricing Analysis

        14.21.2. Market Share Analysis, 2021

            14.21.2.1. By Drug Release

            14.21.2.2. By Distributional Channel

    14.22. Israel

        14.22.1. Pricing Analysis

        14.22.2. Market Share Analysis, 2021

            14.22.2.1. By Drug Release

            14.22.2.2. By Distributional Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Release

        15.3.3. By Distributional Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Pfizer

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

                16.1.1.5.2. Product Strategy

                16.1.1.5.3. Channel Strategy

        16.1.2. Mallinckrodt

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

                16.1.2.5.2. Product Strategy

                16.1.2.5.3. Channel Strategy

        16.1.3. Actavis

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

                16.1.3.5.2. Product Strategy

                16.1.3.5.3. Channel Strategy

        16.1.4. Janssen Pharmaceuticals

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

                16.1.4.5.2. Product Strategy

                16.1.4.5.3. Channel Strategy

        16.1.5. Endo Pharmaceuticals

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

                16.1.5.5.2. Product Strategy

                16.1.5.5.3. Channel Strategy

        16.1.6. Purdue Pharma

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

                16.1.6.5.2. Product Strategy

                16.1.6.5.3. Channel Strategy

        16.1.7. Lavipharm Labs

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

                16.1.7.5.2. Product Strategy

                16.1.7.5.3. Channel Strategy

        16.1.8. Viatris

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

                16.1.8.5.2. Product Strategy

                16.1.8.5.3. Channel Strategy

        16.1.9. Noven

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

                16.1.9.5.2. Product Strategy

                16.1.9.5.3. Channel Strategy

        16.1.10. Aveva

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

                16.1.10.5.2. Product Strategy

                16.1.10.5.3. Channel Strategy

        16.1.11. Watson

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

                16.1.11.5.2. Product Strategy

                16.1.11.5.3. Channel Strategy

        16.1.12. Impax

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

                16.1.12.5.2. Product Strategy

                16.1.12.5.3. Channel Strategy

        16.1.13. Ranbaxy

            16.1.13.1. Overview

            16.1.13.2. Product Portfolio

            16.1.13.3. Profitability by Market Segments

            16.1.13.4. Sales Footprint

            16.1.13.5. Strategy Overview

                16.1.13.5.1. Marketing Strategy

                16.1.13.5.2. Product Strategy

                16.1.13.5.3. Channel Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Extended Release Drugs Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Extended Release Drugs Market Volume (Tons) Forecast by Region, 2017-2032

Table 3: Global Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 4: Global Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 5: Global Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 6: Global Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 7: North America Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 8: North America Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 9: North America Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 10: North America Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 11: North America Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 12: North America Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 13: Latin America Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Latin America Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 15: Latin America Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 16: Latin America Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 17: Latin America Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 18: Latin America Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 19: Europe Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 20: Europe Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 21: Europe Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 22: Europe Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 23: Europe Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 24: Europe Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 25: East Asia Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 26: East Asia Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 27: East Asia Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 28: East Asia Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 29: East Asia Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 30: East Asia Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 31: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 32: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 33: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 34: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 35: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 36: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 37: MEA Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 38: MEA Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 39: MEA Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032

Table 40: MEA Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032

Table 41: MEA Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 42: MEA Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 2: Global Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 3: Global Extended Release Drugs Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global Extended Release Drugs Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 5: Global Extended Release Drugs Market Volume (Tons) Analysis by Region, 2017-2032

Figure 6: Global Extended Release Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Extended Release Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 9: Global Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 10: Global Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 11: Global Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 12: Global Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 13: Global Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 14: Global Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 15: Global Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 16: Global Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 17: Global Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 18: Global Extended Release Drugs Market Attractiveness by Region, 2022-2032

Figure 19: North America Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 20: North America Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 21: North America Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 22: North America Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 23: North America Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 24: North America Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 25: North America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 26: North America Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 27: North America Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 28: North America Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 29: North America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 30: North America Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 31: North America Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 32: North America Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 33: North America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 34: North America Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 35: North America Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 36: North America Extended Release Drugs Market Attractiveness by Country, 2022-2032

Figure 37: Latin America Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 38: Latin America Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 39: Latin America Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 40: Latin America Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 41: Latin America Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 42: Latin America Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 43: Latin America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 44: Latin America Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 45: Latin America Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 46: Latin America Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 47: Latin America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 48: Latin America Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 49: Latin America Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 50: Latin America Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 51: Latin America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 52: Latin America Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 53: Latin America Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 54: Latin America Extended Release Drugs Market Attractiveness by Country, 2022-2032

Figure 55: Europe Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 56: Europe Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 57: Europe Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 58: Europe Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 59: Europe Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 60: Europe Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 61: Europe Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 62: Europe Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 63: Europe Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 64: Europe Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 65: Europe Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 66: Europe Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 67: Europe Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 68: Europe Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 69: Europe Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 70: Europe Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 71: Europe Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 72: Europe Extended Release Drugs Market Attractiveness by Country, 2022-2032

Figure 73: East Asia Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 74: East Asia Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 75: East Asia Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 76: East Asia Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 77: East Asia Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 78: East Asia Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 79: East Asia Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 80: East Asia Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 81: East Asia Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 82: East Asia Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 83: East Asia Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 84: East Asia Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 85: East Asia Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 86: East Asia Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 87: East Asia Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 88: East Asia Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 89: East Asia Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 90: East Asia Extended Release Drugs Market Attractiveness by Country, 2022-2032

Figure 91: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 92: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 93: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 94: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 95: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 96: South Asia & Pacific Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 97: South Asia & Pacific Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 98: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 99: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 100: South Asia & Pacific Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 101: South Asia & Pacific Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 102: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 103: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 104: South Asia & Pacific Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 105: South Asia & Pacific Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 106: South Asia & Pacific Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 107: South Asia & Pacific Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 108: South Asia & Pacific Extended Release Drugs Market Attractiveness by Country, 2022-2032

Figure 109: MEA Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032

Figure 110: MEA Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 111: MEA Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 112: MEA Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 113: MEA Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 114: MEA Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 115: MEA Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 116: MEA Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032

Figure 117: MEA Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032

Figure 118: MEA Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032

Figure 119: MEA Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032

Figure 120: MEA Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 121: MEA Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 122: MEA Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 123: MEA Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 124: MEA Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032

Figure 125: MEA Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 126: MEA Extended Release Drugs Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Orphan Drugs Market

Published : February 2016

Healthcare

Systemic Lupus Erythematous SLE Drugs Market

Published : March 2022

Healthcare

Companion Animal Drugs Market

Published : October 2019

Healthcare

General Anesthesia Drugs Market

Published : August 2015

Google translate

Extended Release Drugs Market